Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Journeytcon Jun 25, 2024 6:43pm
126 Views
Post# 36106019

RE:RE:RE:RE:Time's Up...

RE:RE:RE:RE:Time's Up...Quentin i think understand your logic but have a different take.   Knocking off critical path tasks matters most. Critical path items define when paleo goes to market and when a take over is most likely.  Announcement of mBC oversll survival  results is not on that list.

Critical path items include:

Conclusion of type c meeting
Submissiom of phase 3 documentation
Approval of phase 3
First enrollment
Etc.

We know from interim results paleo is a contender.  Year end results might increase confidence a bit and improve market outlook. 
 Timing to market is most important.  Weve had 25 years of trials and results.   Its time to show us when this company will have positive earnings.
<< Previous
Bullboard Posts
Next >>